(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Eton Pharmaceuticals, Groupon, and CleanSpark.

The three biggest losers today are Cemtrex, Epsilon Energy Ltd., and DarioHealth Corp..

Winners today

1. Eton Pharmaceuticals (ETON) – 26.81%

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

NASDAQ ended the session with Eton Pharmaceuticals rising 26.81% to $3.30 on Friday, following the last session’s downward trend. NASDAQ dropped 0.68% to $13,644.85, following the last session’s upward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Eton Pharmaceuticals has a trailing twelve months EPS of $-0.24.

Sales Growth

Eton Pharmaceuticals’s sales growth is 230.8% for the current quarter and 1.2% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Eton Pharmaceuticals’s EBITDA is -38.01.

Moving Average

Eton Pharmaceuticals’s value is under its 50-day moving average of $3.32 and below its 200-day moving average of $3.37.

Volume

Today’s last reported volume for Eton Pharmaceuticals is 13939300 which is 25166.5% above its average volume of 55169.

More news about Eton Pharmaceuticals.

2. Groupon (GRPN) – 21.13%

Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with Groupon rising 21.13% to $9.20 on Friday while NASDAQ fell 0.68% to $13,644.85.

Earnings Per Share

As for profitability, Groupon has a trailing twelve months EPS of $-8.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -285.15%.

Volatility

Groupon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.00%, a positive 0.49%, and a positive 5.80%.

Groupon’s highest amplitude of average volatility was 3.26% (last week), 4.56% (last month), and 5.80% (last quarter).

Previous days news about Groupon

• Groupon (grpn) reports Q2 loss, tops revenue estimates. According to Zacks on Wednesday, 9 August, "While Groupon has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"

More news about Groupon.

3. CleanSpark (CLSK) – 16.04%

CleanSpark, Inc. engages in the mining of bitcoin operations. It also provides data center services, including rack space, power, and equipment; and various cloud services, such as virtual, virtual storage, and data backup services. The company was formerly known as Stratean Inc. and changed its name to CleanSpark, Inc. in November 2016. CleanSpark, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.

NASDAQ ended the session with CleanSpark jumping 16.04% to $5.86 on Friday, following the last session’s upward trend. NASDAQ slid 0.68% to $13,644.85, following the last session’s upward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, CleanSpark has a trailing twelve months EPS of $-2.07.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.33%.

Moving Average

CleanSpark’s value is way above its 50-day moving average of $5.20 and way higher than its 200-day moving average of $3.52.

Volume

Today’s last reported volume for CleanSpark is 20041200 which is 99.31% above its average volume of 10055200.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 84.8% and 89.1%, respectively.

More news about CleanSpark.

4. SmileDirectClub (SDC) – 14.19%

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a customer's dentist or orthodontist, and facilitating remote clinical monitoring through a network of orthodontists and general dentists through its proprietary teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

NASDAQ ended the session with SmileDirectClub jumping 14.19% to $0.58 on Friday while NASDAQ fell 0.68% to $13,644.85.

Earnings Per Share

As for profitability, SmileDirectClub has a trailing twelve months EPS of $-2.628.

More news about SmileDirectClub.

5. Conifer Holdings (CNFR) – 13.22%

Conifer Holdings, Inc., an insurance holding company, engages in the sale of property and casualty insurance products. It offers insurance coverage in specialty commercial and personal product lines. The company underwrites various specialty insurance products, including property, general liability, liquor liability, automobile, and homeowners and dwelling policies. It serves the commercial insurance needs of owner-operated businesses in the markets, such as hospitality, which includes restaurants, bars, taverns, and bowling centers, as well as small grocery and convenience stores; artisan contractors comprising plumbers, painters, carpenters, electricians, and other independent contractors; and security service providers, including companies that provide security guard services, security alarm products and services, and private investigative services. The company also offers specialty homeowners insurance products, such as low- value dwelling insurance tailored for owners of lower valued homes in Illinois, Indiana, Louisiana, and Texas; and wholesale agency services comprising commercial and personal lines insurance products for its insurance company subsidiaries, as well as third party insurers. Conifer Holdings, Inc. markets and sells its insurance products through a network of approximately 4,900 independent agents in 50 states in the United States. The company was incorporated in 2009 and is headquartered in Troy, Michigan.

NASDAQ ended the session with Conifer Holdings rising 13.22% to $1.37 on Friday, following the last session’s upward trend. NASDAQ fell 0.68% to $13,644.85, following the last session’s upward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Conifer Holdings has a trailing twelve months EPS of $-0.58.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -25.86%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 48% and 115.4%, respectively.

More news about Conifer Holdings.

6. Ebix (EBIX) – 13%

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.

NASDAQ ended the session with Ebix jumping 13% to $16.71 on Friday, after four consecutive sessions in a row of losses. NASDAQ slid 0.68% to $13,644.85, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Ebix has a trailing twelve months EPS of $1.71.

PE Ratio

Ebix has a trailing twelve months price to earnings ratio of 9.77. Meaning, the purchaser of the share is investing $9.77 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.31%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 61.9% and a negative 45.8%, respectively.

More news about Ebix.

7. Diffusion Pharmaceuticals (DFFN) – 11.78%

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

NASDAQ ended the session with Diffusion Pharmaceuticals rising 11.78% to $3.51 on Friday while NASDAQ fell 0.68% to $13,644.85.

Earnings Per Share

As for profitability, Diffusion Pharmaceuticals has a trailing twelve months EPS of $-7.11.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -63.96%.

Volume

Today’s last reported volume for Diffusion Pharmaceuticals is 22456 which is 168.99% above its average volume of 8348.

More news about Diffusion Pharmaceuticals.

8. Deciphera Pharmaceuticals (DCPH) – 11.5%

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing medicines to improve the lives of cancer patients in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 in combination with RTK/RAS/MAP kinase signaling pathway inhibition to treat RAS/RAF mutant cancers. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

NASDAQ ended the session with Deciphera Pharmaceuticals jumping 11.5% to $15.32 on Friday, after three sequential sessions in a row of gains. NASDAQ fell 0.68% to $13,644.85, following the last session’s upward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Deciphera Pharmaceuticals has a trailing twelve months EPS of $-2.14.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.24%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Deciphera Pharmaceuticals’s EBITDA is 6.29.

Volume

Today’s last reported volume for Deciphera Pharmaceuticals is 1736960 which is 277.53% above its average volume of 460080.

More news about Deciphera Pharmaceuticals.

9. Cardiff Oncology (CRDF) – 8.38%

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

NASDAQ ended the session with Cardiff Oncology jumping 8.38% to $2.07 on Friday, following the last session’s upward trend. NASDAQ dropped 0.68% to $13,644.85, following the last session’s upward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Cardiff Oncology has a trailing twelve months EPS of $-0.89.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.29%.

More news about Cardiff Oncology.

10. Citius Pharmaceuticals (CTXR) – 8.2%

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

NASDAQ ended the session with Citius Pharmaceuticals rising 8.2% to $1.00 on Friday while NASDAQ fell 0.68% to $13,644.85.

Earnings Per Share

As for profitability, Citius Pharmaceuticals has a trailing twelve months EPS of $-0.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -29.5%.

Volume

Today’s last reported volume for Citius Pharmaceuticals is 2468500 which is 36.63% above its average volume of 1806690.

Moving Average

Citius Pharmaceuticals’s worth is way under its 50-day moving average of $1.17 and way below its 200-day moving average of $1.18.

Yearly Top and Bottom Value

Citius Pharmaceuticals’s stock is valued at $1.00 at 17:32 EST, way below its 52-week high of $1.71 and way above its 52-week low of $0.77.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Citius Pharmaceuticals’s EBITDA is -12.69.

More news about Citius Pharmaceuticals.

Losers Today

1. Cemtrex (CETXP) – -10.26%

Cemtrex, Inc. operates as a technology company in the United States and internationally. The company operates through Advanced Technologies and Industrial Services segments. The Advanced Technologies segment provides Internet of Things products and smart devices under the SmartDesk name for mobile, web, virtual and augmented reality, wearables, and television markets; and security and video surveillance solutions, and virtual and augmented reality solutions for various commercial and industrial applications. This segment also offers browser-based video monitoring systems and analytics-based recognition systems, cameras, servers, and access control systems for security and surveillance in industrial and commercial facilities, federal prisons, hospitals, universities, schools, and federal and state government offices. The Industrial Services segment provides single-source services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly; installs high precision equipment in various industrial markets comprising automotive, printing and graphics, industrial automation, packaging, chemicals and others; and provides maintenance and contracting solutions for the machinery, packaging, printing, chemical, and other manufacturing markets. The company was formerly known as Diversified American Holding, Inc. and changed its name to Cemtrex, Inc. in December 2004. Cemtrex, Inc. was incorporated in 1998 and is headquartered in Brooklyn, New York.

NASDAQ ended the session with Cemtrex sliding 10.26% to $0.70 on Friday, after four sequential sessions in a row of losses. NASDAQ slid 0.68% to $13,644.85, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Cemtrex has a trailing twelve months EPS of $-0.825.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.1%.

Volume

Today’s last reported volume for Cemtrex is 5383 which is 12.93% below its average volume of 6183.

Revenue Growth

Year-on-year quarterly revenue growth grew by 36.8%, now sitting on 57.16M for the twelve trailing months.

Yearly Top and Bottom Value

Cemtrex’s stock is valued at $0.70 at 17:32 EST, way under its 52-week high of $1.16 and way above its 52-week low of $0.22.

More news about Cemtrex.

2. Epsilon Energy Ltd. (EPSN) – -8.93%

Epsilon Energy Ltd., a natural gas and oil company, engages in the acquisition, development, gathering, and production of oil and gas reserves in the United States. It operates through Upstream and Gathering System segments. The company primarily focuses on the Marcellus Shale comprising 3,979 net acres located in the Susquehanna County, Pennsylvania; and Anadarko basin comprising 8,594 net acres located in the Oklahoma. As of December 31, 2020, it had total estimated net proved reserves of 88,658 million cubic feet of natural gas reserves and 371,343 barrels of oil and other liquids. Epsilon Energy Ltd. was incorporated in 2005 and is based in Houston, Texas.

NASDAQ ended the session with Epsilon Energy Ltd. falling 8.93% to $5.71 on Friday while NASDAQ dropped 0.68% to $13,644.85.

Earnings Per Share

As for profitability, Epsilon Energy Ltd. has a trailing twelve months EPS of $1.43.

PE Ratio

Epsilon Energy Ltd. has a trailing twelve months price to earnings ratio of 3.99. Meaning, the purchaser of the share is investing $3.99 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.98%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 13, 2023, the estimated forward annual dividend rate is 0.25 and the estimated forward annual dividend yield is 3.99%.

Yearly Top and Bottom Value

Epsilon Energy Ltd.’s stock is valued at $5.71 at 17:32 EST, way below its 52-week high of $7.66 and way above its 52-week low of $4.76.

More news about Epsilon Energy Ltd..

3. DarioHealth Corp. (DRIO) – -8.43%

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.

NASDAQ ended the session with DarioHealth Corp. sliding 8.43% to $3.15 on Friday, after two successive sessions in a row of losses. NASDAQ dropped 0.68% to $13,644.85, following the last session’s upward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, DarioHealth Corp. has a trailing twelve months EPS of $-2.47.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 26.6% and 15.7%, respectively.

Sales Growth

DarioHealth Corp.’s sales growth for the next quarter is 11.9%.

More news about DarioHealth Corp..

4. Canopy Growth (CGC) – -8.26%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth dropping 8.26% to $0.40 on Friday, after three consecutive sessions in a row of losses. NASDAQ slid 0.68% to $13,644.85, following the last session’s upward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-5.4.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -151.11%.

More news about Canopy Growth.

5. Futu Holdings (FUTU) – -7.84%

Futu Holdings Limited provides digitalized securities brokerage and wealth management product distribution service in Hong Kong and internationally. It offers online financial services, including securities and derivative trades brokerage, margin financing and fund distribution services through its Futubull and Moomoo digital platforms. The company also provides financial information and online community services; online wealth management services under the brand of Money Plus through its Futubull and moomoo platforms, which give access to mutual funds, private funds, and bonds; market data and information services; and NiuNiu Community, which serves as an open forum for users and clients to share insights, ask questions, and exchange ideas. In addition, the company provides initial public offering subscription and employee share option plan solution services. Futu Holdings Limited was founded in 2007 and is based in Sheung Wan, Hong Kong.

NASDAQ ended the session with Futu Holdings sliding 7.84% to $49.51 on Friday while NASDAQ dropped 0.68% to $13,644.85.

Earnings Per Share

As for profitability, Futu Holdings has a trailing twelve months EPS of $3.53.

PE Ratio

Futu Holdings has a trailing twelve months price to earnings ratio of 14.03. Meaning, the purchaser of the share is investing $14.03 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.67%.

Volatility

Futu Holdings’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.64%, a positive 0.99%, and a positive 2.69%.

Futu Holdings’s highest amplitude of average volatility was 1.64% (last week), 3.35% (last month), and 2.69% (last quarter).

Yearly Top and Bottom Value

Futu Holdings’s stock is valued at $49.51 at 17:32 EST, way below its 52-week high of $72.20 and way above its 52-week low of $28.00.

More news about Futu Holdings.

6. Super Micro Computer (SMCI) – -7.5%

Super Micro Computer, Inc., together with its subsidiaries, develops and manufactures high performance server and storage solutions based on modular and open architecture in the United States, Europe, Asia, and internationally. Its solutions range from complete server, storage systems, modular blade servers, blades, workstations, full racks, networking devices, server sub-systems, server management software, and security software. The company also provides application-optimized server solutions, rackmount and blade servers, storage, and subsystems and accessories; and server software management solutions, such as Server Management Suite, including Supermicro Server Manager, Supermicro Power Management software, Supermicro Update Manager, SuperCloud Composer, and SuperDoctor 5. In addition, it offers server subsystems and accessories comprising server boards, chassis, power supplies, and other accessories. Further, the company provides server and storage system integration, configuration, and software upgrade and update services; and technical documentation services, as well as identifies service requirements, creates and executes project plans, and conducts verification testing and training services. Additionally, it offers help desk and on-site product support services for its server and storage systems; and customer support services, including ongoing maintenance and technical support for its products. The company provides its products to enterprise data centers, cloud computing, artificial intelligence, and 5G and edge computing markets. It sells its products through direct and indirect sales force, distributors, value-added resellers, system integrators, and original equipment manufacturers. Super Micro Computer, Inc. was incorporated in 1993 and is headquartered in San Jose, California.

NASDAQ ended the session with Super Micro Computer sliding 7.5% to $256.33 on Friday, following the last session’s upward trend. NASDAQ fell 0.68% to $13,644.85, following the last session’s upward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Super Micro Computer has a trailing twelve months EPS of $10.47.

PE Ratio

Super Micro Computer has a trailing twelve months price to earnings ratio of 24.48. Meaning, the purchaser of the share is investing $24.48 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 38.6%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is 19.8% and a drop 13.5% for the next.

Volume

Today’s last reported volume for Super Micro Computer is 3211260 which is 2.76% above its average volume of 3124720.

Moving Average

Super Micro Computer’s value is higher than its 50-day moving average of $247.26 and way above its 200-day moving average of $129.92.

More news about Super Micro Computer.

7. Aspen Group (ASPU) – -7.5%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group falling 7.5% to $0.15 on Friday while NASDAQ slid 0.68% to $13,644.85.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.36.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Yearly Top and Bottom Value

Aspen Group’s stock is valued at $0.15 at 17:32 EST, way below its 52-week high of $1.10 and way above its 52-week low of $0.03.

More news about Aspen Group.

8. Corvus Pharmaceuticals (CRVS) – -7.36%

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

NASDAQ ended the session with Corvus Pharmaceuticals dropping 7.36% to $2.14 on Friday while NASDAQ dropped 0.68% to $13,644.85.

Earnings Per Share

As for profitability, Corvus Pharmaceuticals has a trailing twelve months EPS of $-0.78.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.1%.

Yearly Top and Bottom Value

Corvus Pharmaceuticals’s stock is valued at $2.14 at 17:32 EST, way below its 52-week high of $4.19 and way higher than its 52-week low of $0.61.

Volume

Today’s last reported volume for Corvus Pharmaceuticals is 220835 which is 76.8% below its average volume of 952053.

More news about Corvus Pharmaceuticals.

9. DIRTT Environmental Solutions Ltd. (DRTT) – -7.24%

DIRTT Environmental Solutions Ltd. designs, manufactures, and installs prefabricated interior solutions for use primarily in commercial spaces across various industries and businesses in the United States, Canada, internationally. Its ICE software interior construction technology provides integration and management, from design through engineering, manufacturing, and installation. The company's interior construction solutions include prefabricated, customized interior modular walls, ceilings, and floors; decorative and functional millwork; power infrastructure; network infrastructure; and pre-installed medical gas piping systems. It offers interior construction solutions through a network of independent distribution partners. It serves commercial, healthcare, education, hospitality, and other industries, as well as medical gas piping systems for healthcare. DIRTT Environmental Solutions Ltd. was incorporated in 2003 and is headquartered in Calgary, Canada.

NASDAQ ended the session with DIRTT Environmental Solutions Ltd. falling 7.24% to $0.40 on Friday while NASDAQ dropped 0.68% to $13,644.85.

Earnings Per Share

As for profitability, DIRTT Environmental Solutions Ltd. has a trailing twelve months EPS of $-0.55.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -112.25%.

Moving Average

DIRTT Environmental Solutions Ltd.’s worth is way higher than its 50-day moving average of $0.31 and under its 200-day moving average of $0.43.

Yearly Top and Bottom Value

DIRTT Environmental Solutions Ltd.’s stock is valued at $0.40 at 17:32 EST, way under its 52-week high of $1.07 and way higher than its 52-week low of $0.20.

Revenue Growth

Year-on-year quarterly revenue growth grew by 0.1%, now sitting on 170.64M for the twelve trailing months.

More news about DIRTT Environmental Solutions Ltd..

10. DAQO New Energy (DQ) – -6.88%

Daqo New Energy Corp., together with its subsidiaries, manufactures and sells polysilicon to photovoltaic product manufacturers in the People's Republic of China. Its products are used in ingots, wafers, cells, and modules for solar power solutions. The company was formerly known as Mega Stand International Limited and changed its name to Daqo New Energy Corp. in August 2009. Daqo New Energy Corp. was founded in 2006 and is based in Shanghai, the People's Republic of China.

NYSE ended the session with DAQO New Energy falling 6.88% to $35.16 on Friday while NYSE jumped 0.05% to $16,143.38.

Earnings Per Share

As for profitability, DAQO New Energy has a trailing twelve months EPS of $19.74.

PE Ratio

DAQO New Energy has a trailing twelve months price to earnings ratio of 1.78. Meaning, the purchaser of the share is investing $1.78 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 42.76%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

DAQO New Energy’s EBITDA is 7.82.

Volume

Today’s last reported volume for DAQO New Energy is 539268 which is 44.66% below its average volume of 974575.

Volatility

DAQO New Energy’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.04%, a negative 0.14%, and a positive 2.23%.

DAQO New Energy’s highest amplitude of average volatility was 2.49% (last week), 2.46% (last month), and 2.23% (last quarter).

More news about DAQO New Energy.

Stay up to date with our winners and losers daily report